A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Trial details
- Registry ID
- NCT05980806
- Phase
- Phase 2
The FDA approved Pacritinib (VONJO) on 28 Feb 2022.
Drug identity checked against registry records
Also recorded as VONJO
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806 | KPTI | Phase 2 | Recruiting | 2027-06Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-02-28Day | Pacritinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA208712", "applicant_as_listed_by_fda": "SOBI", "brand_names": ["VONJO"], "active_ingredients": ["PACRITINIB CITRATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220228", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |